Great progress! After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year. In the trial, the vaccine was given to pregnant people and appeared to be about 80% effective at preventing severe RSV disease in their infants in the first three months of life. It also cut a baby’s risk of needing to see a doctor for an RSV infection by half.
Posted by Hand to Hold at 2022-12-12 14:00:29 UTC